<DOC>
	<DOCNO>NCT01371045</DOCNO>
	<brief_summary>The purpose study test effect long-acting somatostatin analog medication , take patient acromegaly carcinoid syndrome , growth hormone comparison healthy control receive medication order see whether medication make oral glucose test less accurate . The Oral Glucose Tolerance Test ( OGTT ) standard test measure growth hormone secretion . By compare GH responses non-acromegaly subject take somatostatin analog treatment , relative contribution medication underlie disease state analyze .</brief_summary>
	<brief_title>Oral Glucose Tolerance Testing ( OGTT ) Patients Taking Somatostatin Analogs</brief_title>
	<detailed_description>Subjects inform study provide write informed consent , subject ask undergo 2-hour oral glucose tolerance test ( ingestion 75g glucose subsequent time assessment growth hormone , glucose , insulin relate binding protein . ) Baseline assessment hormone may contribute result draw , prior perform test . Patients ask complete one visit total participate trial .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Diagnosis acromegaly carcinoid syndrome Treatment somatostatin analog therapy ( must establish stable dose three injection dose prior study enrollment ) Healthy control subject Diagnosis Diabetes Mellitus ( Type 1 Type 2 ) Use medication treatment insulin resistance diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>Carcinoid Syndrome</keyword>
	<keyword>Somatostatin</keyword>
</DOC>